Positive reviews highlight its gentle formula and the absence of jittery side effects common in stimulant-based products
The results are never completely predictable
Eligible participants were 18 years or older and had type 2 diabetes treated with a combination of metformin, sulfonylurea, or sodium-glucose co-transporter-2 inhibitor
BENIN AL, VITKAUSKAS G, THORNQUIST E, SHIFFMAN RN, CONCATO J, KRUMHOLZ HM , SHAPIRO ED
This triple mechanism of action distinguishes retatrutide from currently approved medicines such as semaglutide (a GLP-1 receptor agonist) and tirzepatide (a dual GIP/GLP-1 receptor agonist)
The level of physician supervision represents perhaps the most critical difference between US and Mexican peptide therapy options